Business Context and Reporting Period
Company: Inmed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 27, 2026
Reporting Period: The filing addresses a specific event occurring on March 27, 2026, regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding share price.
Material Changes
Nasdaq Non-Compliance Notice: On March 27, 2026, the Company received written notice from Nasdaq that its common shares failed to meet the minimum $1.00 per share closing bid price requirement for 30 consecutive trading days (February 11, 2026, to March 26, 2026) under Listing Rule 5550(a)(2).
Current Status: The shares continue to trade under the symbol "INM" with no immediate impact on listing status.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 calendar days from the notice date to cure the deficiency and regain compliance.
- Remediation Options: The Company intends to monitor share prices and explore options, which may include effecting a reverse stock split.
- Extension Possibility: If compliance is not met within the initial 180 days, the Company may be eligible for an additional 180-day grace period, provided it meets other initial listing standards (excluding bid price) and notifies Nasdaq of its intent to cure.
- Delisting Risk: Failure to regain compliance within the allotted periods may result in delisting. If delisting is notified, trading would be suspended pending an appeal to a Nasdaq Hearings Panel, with no assurance of a successful appeal.
Investor Verification Checklist
- Verify the current closing bid price of INM shares to assess the severity of the deficiency.
- Monitor for announcements regarding a potential reverse stock split or other capital structure changes.
- Track the 180-day compliance deadline to determine if the company is on track to regain listing standards.
- Review the attached press release (Exhibit 99.1) for any additional forward-looking statements or strategic updates not detailed in the 8-K text.